Why hip osteoarthritis involves more than worn cartilage

Advanced hip osteoarthritis rarely presents as a single, contained problem. By the time a joint reaches Kellgren–Lawrence Grade III or IV, two distinct processes are usually running in parallel: the cartilage covering the femoral head and acetabulum has thinned or worn through, reducing the cushioning between bones and generating the grinding, load-related ache that most patients recognise first; and the synovial lining — the membrane that encloses the joint and produces its lubricating fluid — has thickened and become chronically inflamed.

These are not the same problem. Cartilage loss is a structural issue, felt as pain under load and loss of smooth movement. Synovial inflammation is a biological one, driving swelling, morning stiffness, and the sharp flares that often follow activity. Each can worsen the other: degraded cartilage releases breakdown products that irritate the synovium; an inflamed synovium in turn produces enzymes that may accelerate cartilage breakdown.

A programme that addresses only one of these processes leaves the other intact. The staged approach — pairing a regenerative collagen scaffold aimed at the joint surface with a product targeting the synovial lining — follows directly from this anatomy. Neither component substitutes for the other; they are directed at different structures within the same joint.

How ChondroFiller injection works on worn hip cartilage

Injected under ultrasound guidance in an outpatient setting at the London Cartilage Clinic, ChondroFiller is a Type I collagen hydrogel — a CE-marked Class III medical device that transitions from liquid to a viscoelastic gel once it contacts the warm, fluid environment of the joint. Rather than filling a void or acting as a lubricant, the scaffold creates a biological matrix over the worn cartilage surface, into which the patient's own progenitor cells — drawn from the surrounding synovium and subchondral bone — can migrate and begin the repair process. The mechanism is acellular matrix-induced chondrogenesis: the device provides the structure; the body provides the cells.

Because the collagen is applied top-down over existing wear without any requirement to debride or prepare the surface first, ChondroFiller is not restricted to focal, contained lesions. This matters particularly in the hip, where diffuse cartilage loss across the femoral head and acetabulum — typical of Kellgren–Lawrence Grade III or IV disease — is the rule rather than the exception.

Hip-specific clinical evidence comes from Perez-Carro et al. (2021), which recorded an approximately 30-point improvement in the modified Harris Hip Score (mHHS), a validated measure of hip pain and function. ChondroFiller does not claim to regrow cartilage; it creates the conditions in which endogenous repair can occur — and the mHHS data suggest meaningful functional gains can follow. Across all treated joints, over 20,000 implantations carried out in more than ten years support its safety profile.

No operating theatre is required. The injection is delivered by an image-guided clinician at the London Cartilage Clinic on Harley Street, and the procedure is completed as an outpatient appointment.

What Arthrosamid does to the synovial lining

Arthrosamid works through a mechanism that has nothing in common with cartilage repair. The product — a 2.5% cross-linked polyacrylamide hydrogel (iPAAG), manufactured by Contura International in Denmark and delivered as a single 6 mL intra-articular injection — is progressively absorbed into the synovial lining. Synovial cells infiltrate the gel within 10 to 14 days; by 30 to 90 days a stable sub-synovial cushioning layer has formed, traversed by connective tissue and small vessels. Pre-clinical data in horse and rabbit joints show this structure persisting for up to two years post-injection. The process is characterised as a low-level, macrophage-driven foreign body response — controlled enough to be tolerated, but sufficient to anchor the gel in place.

Its role is mechanical buffering of the synovial compartment and dampening of intra-articular load. It does not address the surface wear that ChondroFiller targets, and it is not a regenerative therapy.

Regulatory status: knee only

Arthrosamid holds a licensed indication for symptomatic knee osteoarthritis in adults. It is not approved for use in the hip. In the context of a hip osteoarthritis programme, any inclusion of Arthrosamid would constitute off-label use, requiring explicit informed consent and a separate, independent clinical justification for that patient.

Three safety considerations are relevant to any informed decision. First, the implant is permanent — once integrated into the synovial lining, it is neither removed nor reabsorbed. Second, concerns exist around residual acrylamide monomer leaching from the polymer matrix; acrylamide is a recognised neurotoxin and suspected carcinogen, and its long-term behaviour within a joint has not been fully characterised. Third, published datasets on post-injection joint effusion rely on patient self-report rather than clinician-assessed endpoints — a study design limitation that may mean inflammatory complications are recorded less consistently than the true rate.

How the staged programme is delivered in practice

The programme runs across two separate outpatient appointments, not one. ChondroFiller injection comes first — delivered under ultrasound guidance at the London Cartilage Clinic on Harley Street, targeting the worn cartilage surface at the femoral head and acetabulum. Arthrosamid follows at a later appointment, injected into the joint cavity to establish its sub-synovial cushioning layer. The two products are never administered in the same session: each requires its own independent clinical assessment beforehand, and staging the appointments allows any early response to the first injection to inform the decision about the second.

Both procedures are outpatient and image-guided — no theatre admission, no general anaesthesia. The precision of each injection matters considerably; outcomes are sensitive to accuracy of placement and the clinician's familiarity with how each product behaves at its intended site. Professor Paul Y. F. Lee, who leads cartilage injection practice at LCC, is the UK clinician delivering this programme.

The combined pathway is structured under two programme names: CFI+ pairs ChondroFiller with Arthrosamid; the extended CFI++ adds autologous mesenchymal stem cells as a third component. Guide pricing for each tier is confirmed by the London Cartilage Clinic at the assessment appointment.

What the evidence shows and where the gaps are

The individual evidence base for each component is substantive. ChondroFiller's knee data — IKDC score gains of approximately 30 points across peer-reviewed cohorts, MOCART repair scores of 81.6 to 84.3, and three-year durability in the Jerosch series — establish structural and functional improvement well above the minimum clinically important threshold. Perez-Carro et al. (2021) extend that picture to the hip specifically, providing joint-relevant evidence that the knee studies alone could not supply. Taken together, ChondroFiller's role in this programme is on-label and evidence-supported.

Arthrosamid's published follow-up in the knee extends to 24 months, with a well-characterised synovial integration mechanism from pre-clinical work. No peer-reviewed cohort or trial has evaluated its use in the hip, and its regulatory approval covers adult knee OA only — placing any hip application formally off-label.

The more fundamental limitation applies to both products in combination: no study has evaluated ChondroFiller and Arthrosamid together directly. The programme is individually evidenced but not combinatorially proven — outcomes from separate product trials cannot be summed to predict what a staged approach will deliver in a given patient. The anatomical rationale is coherent, but coherence is not clinical proof.

What follows from that is a specialist conversation: one that weighs the individual evidence against a patient's hip anatomy, disease stage, and medical history, and sets out clearly what each component is and is not expected to contribute.

Who this programme is likely to suit and how to find out

The practical question most patients arrive at by this stage is not whether the programme makes anatomical sense — that ground has been covered — but whether the evidence gaps are ones they can reasonably accept, given that the realistic comparator for advanced hip OA is joint replacement.

For ChondroFiller injection, the hip data from Perez-Carro et al. (2021) places this component on on-label ground. The harder question concerns Arthrosamid: licensed only for the adult knee, with no published hip-specific cohort to draw on. For patients at Kellgren-Lawrence Grade III or IV who are not yet surgical candidates, that off-label position may be acceptable — particularly where persistent synovial inflammation is a prominent and undertreated symptom — but it requires a structured conversation about the permanence of the implant, the absence of hip-specific evidence, and genuine informed consent. Some patients will proceed with ChondroFiller injection alone; others, having understood both positions clearly, may find the staged programme appropriate to their individual situation.

What the specialist assessment at the London Cartilage Clinic is structured to determine is whether each component has a distinct, defensible role for that patient — not whether the combined programme is generically available.

Liquid Cartilage™ is delivered in the UK at the London Cartilage Clinic on Harley Street. Book an assessment via londoncartilage.com.